Hypolipidemics Flashcards
What is the class for Niacin (Niaspan)
Nicotinic acid
What is the mechanism for Niacin (Niaspan)
Reduction of liver triglyceride synthesis, leading to less hepatic VLDL (thus, LDL) production; decreases lipolysis in adipose tissue, leading to lowered FFA transport to liver (thus, less triglycerides); reduced hepatic clearance of ApoAI (raising HDL)
What are the therapeutics for Niacin (Niaspan)
Best agent to increase HDL (30-40%); as good as fibrates and statins at lowering triglycerides (35-45%); lowers LDL (20-30%); hypertriglyceridemia and low HDL
What are the important side effects for Niacin (Niaspan)
Flushing, pruritis of face and upper trunk, rashes, acanthosis nigricans (hyperpigmentation)
What are the other side effects for Niacin (Niaspan)
Hepatotoxicity, hyperuricemia, hyperglycemia; dyspepsia/reactivation of peptic ulcer disease; rarely, toxic ambylopia, tachyarrhythmias, a-fib (in elderly) and myopathy
What are the miscellaneous for Niacin (Niaspan)
Water soluble B vitamin complex at [low]; hypolipidemic at [high]; side effects limit compliance (<50% eligible patients follow on it); contraindicated in DM and gout patients; prevent flushing and pruritus with ASA
What is the class for Clofibrate (Atromid-S)
Fibric Acid Derivatives (Fibrates)
What is the mechanism for Clofibrate (Atromid-S)
Unknown; may interact w/peroxisome proliferator-activated receptor (esp. PPAR?) to stimulate LPL synthesis (enhance TG-rich lipoprotein clearance); inhibit apoC III expression (enhance VLDL clearance); stimulation of apoAI and apoAII (increase HDL)
What are the therapeutics for Clofibrate (Atromid-S)
Marked reduction in VLDL (thus, triglycerides); variable and small effect on LDL; small increase in HDL (10%); severe hypertriglyceridemia
What are the important side effects for Clofibrate (Atromid-S)
Potentiate oral anticoagulants (displace from albumin), increase bile lithogenicity; myositis flu-like syndrome in 5%, other effects in 10% (not serious)
What are the miscellaneous for Clofibrate (Atromid-S)
Combination w/statin inadvisable due to higher myositis risk
What is the class for Gemfibrozil (Lopid)
Fibric Acid Derivatives (Fibrates)
What is the mechanism for Gemfibrozil (Lopid)
Unknown; may interact w/peroxisome proliferator-activated receptor (esp. PPAR?) to stimulate LPL synthesis (enhance TG-rich lipoprotein clearance); inhibit apoC III expression (enhance VLDL clearance); stimulation of apoAI and apoAII (increase HDL)
What are the therapeutics for Gemfibrozil (Lopid)
Marked reduction in VLDL (thus, triglycerides); variable and small effect on LDL; small increase in HDL (10%); severe hypertriglyceridemia
What are the important side effects for Gemfibrozil (Lopid)
Potentiate oral anticoagulants (displace from albumin), increase bile lithogenicity (less than clofibrate); myositis flu-like syndrome in 5%, other effects in 10% (not serious)
What are the miscellaneous for Gemfibrozil (Lopid)
Combination w/statin inadvisable due to higher myositis risk
What is the class for Fenofibrate (Tricor)
Fibric Acid Derivatives (Fibrates)
What is the mechanism for Fenofibrate (Tricor)
Unknown; may interact w/peroxisome proliferator-activated receptor (esp. PPAR?) to stimulate LPL synthesis (enhance TG-rich lipoprotein clearance); inhibit apoC III expression (enhance VLDL clearance); stimulation of apoAI and apoAII (increase HDL)
What are the therapeutics for Fenofibrate (Tricor)
Marked reduction in VLDL (thus, triglycerides); variable and small effect on LDL; small increase in HDL (10%); severe hypertriglyceridemia
What are the important side effects for Fenofibrate (Tricor)
Potentiate oral anticoagulants (displace from albumin), increase bile lithogenicity (less than clofibrate); myositis flu-like syndrome in 5%, other effects in 10% (not serious)